Skip to content

Advertisement

Open Access

Correction to: Entrapment of an EGFR inhibitor into nanostructured lipid carriers (NLC) improves its antitumor activity against human hepatocarcinoma cells

  • Roberto Di Gesù1,
  • Maria Luisa Bondì2Email author,
  • Antonina Azzolina3,
  • Emanuela Fabiola Craparo4,
  • Chiara Botto4,
  • Erika Amore2,
  • Gaetano Giammona4 and
  • Melchiorre Cervello3
Contributed equally
Journal of Nanobiotechnology201816:3

https://doi.org/10.1186/s12951-017-0325-y

Received: 1 December 2017

Accepted: 1 December 2017

Published: 13 January 2018

The original article was published in Journal of Nanobiotechnology 2014 12:21

Correction to: Journal of Nanobiotechnology 2014, 12:21 https://doi.org/10.1186/1477-3155-12-21

Following publication of our article [1], we became aware that Roberto Di Gesù had been omitted from the list of authors. The corrected author list and authors’ contribution statement appear below. We apologize for any inconvenience this may have caused.

Corrected author list

Roberto Di Gesù, Maria Luisa Bondì, Antonina Azzolina, Emanuela Fabiola Craparo, Chiara Botto, Erika Amore, Gaetano Giammona, Melchiorre Cervello

Corrected Authors’ contributions

CB and EA are the Ph.D. students who carried out the laboratory work. AA carried out the biological work in laboratory. MC was the supervisor of the biological study and helping to develop the study parameters and design. RDG performed principal and most important analysis in the chemical and pharmaceutical studies. He produced materials and analyzed data showed in this work. MLB was the principal, scientific supervisor of the study. She conceived the study, supervised the students in the laboratory, directed the analysis and wrote the manuscript. EFC and GG have revised the final version of manuscript. All authors read and approved the final manuscript.

Competing interests

The authors declare that they have no competing interests.

Notes

Declarations

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Polymer Science Lab, Chemistry Dept “G.Ciamician”, Alma Mater Studiorum, University of Bologna, Bologna, Italy
(2)
Istituto per lo Studio dei Materiali Nanostrutturati, U.O.S. Palermo, Consiglio Nazionale delle Ricerche, Palermo, Italy
(3)
Istituto di Biomedicina e Immunologia Molecolare Alberto Monroy, Consiglio Nazionale delle Ricerche, Palermo, Italy
(4)
Lab. of Biocompatible Polymers, Dipartimento di Scienze e Tecnologie Biologiche Chimiche e Farmaceutiche (STEBICEF), Palermo, Italy

Reference

  1. Di Gesù R, Bondì ML, Azzolina A, Craparo EF, Botto C, Amore E, Giammona G, Cervello M. Entrapment of an EGFR inhibitor into nanostructured lipid carriers (NLC) improves its antitumor activity against human hepatocarcinoma cells. Journal of Nanobiotechnology. 2014;12:21.View ArticleGoogle Scholar

Copyright

© The Author(s) 2018

Advertisement